Design, synthesis and biological evaluation of novel 1, 3, 4, 9-tetrahydropyrano[3, 4-b]indoles as potential treatment of triple negative breast cancer by suppressing PI3K/AKT/mTOR pathway. (1st February 2022)
- Record Type:
- Journal Article
- Title:
- Design, synthesis and biological evaluation of novel 1, 3, 4, 9-tetrahydropyrano[3, 4-b]indoles as potential treatment of triple negative breast cancer by suppressing PI3K/AKT/mTOR pathway. (1st February 2022)
- Main Title:
- Design, synthesis and biological evaluation of novel 1, 3, 4, 9-tetrahydropyrano[3, 4-b]indoles as potential treatment of triple negative breast cancer by suppressing PI3K/AKT/mTOR pathway
- Authors:
- Qin, Jing
Sun, Xia
Ma, Yingang
Cheng, Yahong
Ma, Qiushuang
Jing, Weiqiang
Qu, Sifeng
Liu, Lei - Abstract:
- Graphical abstract: Highlights: Molecular hybridization is a useful tool for construction of small molecule library. Compound 23 possess anti-cancer effects and selectivity against MDA-MB-231 cells. Compound 23 showed inhibitory effect against PI3K/AKT/mTOR pathway. Compound 23 is novel TNBC drug candidate by inducing cell cycle arrest and apoptosis. Abstract: Triple-negative breast cancer (TNBC) represents a subset of breast cancer characterized by high aggressiveness and poor prognosis. Currently, there is no curative therapeutic regimen for TNBC patients. In this study, molecular hybridization strategy is adopted by combining benzopyran and indole pharmacophores together, and a library of structurally simple 1, 3, 4, 9-tetrahydropyrano[3, 4- b ]indoles was rapidly constructed. The structure-activity relationship studies indicated that compound 23 exhibited the most potent effect against the MDA-MB-231 cells with IC50 value of 2.29 μM. Mechanistic studies revealed that compound 23 inhibited cell proliferation via arresting cell cycle at G0/G1 phase. It induced cell apoptosis by disruption of mitochondrial membrane potential (MMP), accumulation of reactive oxygen species (ROS), reduction of glutathione (GSH), elevation of intracellular calcium ion (Ca 2+ ) and activation of caspase cascade. Furthermore, compound 23 significantly inhibited the regulators of PI3K/AKT/mTOR pathway in MDA-MB-231 cells, suggesting that PI3K/AKT/mTOR pathway was involved in the 23- mediatedGraphical abstract: Highlights: Molecular hybridization is a useful tool for construction of small molecule library. Compound 23 possess anti-cancer effects and selectivity against MDA-MB-231 cells. Compound 23 showed inhibitory effect against PI3K/AKT/mTOR pathway. Compound 23 is novel TNBC drug candidate by inducing cell cycle arrest and apoptosis. Abstract: Triple-negative breast cancer (TNBC) represents a subset of breast cancer characterized by high aggressiveness and poor prognosis. Currently, there is no curative therapeutic regimen for TNBC patients. In this study, molecular hybridization strategy is adopted by combining benzopyran and indole pharmacophores together, and a library of structurally simple 1, 3, 4, 9-tetrahydropyrano[3, 4- b ]indoles was rapidly constructed. The structure-activity relationship studies indicated that compound 23 exhibited the most potent effect against the MDA-MB-231 cells with IC50 value of 2.29 μM. Mechanistic studies revealed that compound 23 inhibited cell proliferation via arresting cell cycle at G0/G1 phase. It induced cell apoptosis by disruption of mitochondrial membrane potential (MMP), accumulation of reactive oxygen species (ROS), reduction of glutathione (GSH), elevation of intracellular calcium ion (Ca 2+ ) and activation of caspase cascade. Furthermore, compound 23 significantly inhibited the regulators of PI3K/AKT/mTOR pathway in MDA-MB-231 cells, suggesting that PI3K/AKT/mTOR pathway was involved in the 23- mediated apoptosis. To our knowledge, this is the first example of the anti-cancer activity study of indole-fused pyrans through suppressing PI3K/AKT/mTOR pathway. Overall, the current study suggested that compound 23 would serve as a promising lead compound for TNBC treatment. … (more)
- Is Part Of:
- Bioorganic & medicinal chemistry. Volume 55(2022)
- Journal:
- Bioorganic & medicinal chemistry
- Issue:
- Volume 55(2022)
- Issue Display:
- Volume 55, Issue 2022 (2022)
- Year:
- 2022
- Volume:
- 55
- Issue:
- 2022
- Issue Sort Value:
- 2022-0055-2022-0000
- Page Start:
- Page End:
- Publication Date:
- 2022-02-01
- Subjects:
- Triple negative breast cancer -- 1, 3, 4, 9-Tetrahydropyrano[3, 4-b] indoles -- Molecular hybridization -- PI3K/AKT/mTOR pathway -- Apoptosis
Bioorganic chemistry -- Periodicals
Pharmaceutical chemistry -- Periodicals
Biochemistry -- Periodicals
Chemistry, Clinical -- Periodicals
Chemistry, Organic -- Periodicals
Chimie bio-organique -- Périodiques
Chimie pharmaceutique -- Périodiques
615.19 - Journal URLs:
- http://www.sciencedirect.com/science/journal/09680896 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.bmc.2021.116594 ↗
- Languages:
- English
- ISSNs:
- 0968-0896
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 2089.325000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 20347.xml